Skip to main content
. 2019 Mar 19;10:453. doi: 10.3389/fimmu.2019.00453

Table 4.

Selection of current A2AR/CD73 inhibitor clinical trials. Information sourced from ClinicalTrials.gov.

Trial Aim Target molecules Condition Phase
NCT03454451 To evaluate the safety, tolerability, and anti-tumor activity of CPI-006 as a single agent, in combination with A2AR inhibitor CPI-444 and in combination with pembrolizumab CPI-006: CD23 and adenosine inhibitor CPI-444: A2AR inhibitor Pembrolizumab: humanized anti-PD-1 mAb • Non-small cell lung Cancer (NSCLC)
• Renal cell cancer
• Colorectal cancer
• Triple negative breast cancer
• Cervical cancer
• Ovarian cancer
• Pancreatic cancer
• Endometrial cancer
• Sarcoma
• Squamous cell Carcinoma of the head and neck
• Bladder cancer
• Metastatic castration Resistant prostate cancer
I
NCT02503774 To evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI9447 (oleclumab) alone and in combination with MEDI4736 (Durvalumab) in adult subjects with select advanced solid tumors Oleclumab: human anti-CD73 mAb Durvalumab: human anti-PD-1 mAb • Advanced solid malignancies
• NSCLC
I
NCT02655822 To study the safety, tolerability, and anti-tumor activity of A2Ar inhibitor CPI-444 alone and in combination with atezolizumab CPI-444: A2AR inhibitor Atezolizumab: humanized anti-PD-1 mAb • Non-small cell lung cancer
• Malignant melanoma
• Renal cell cancer
• Triple negative breast cancer
• Colorectal cancer
• Bladder cancer
• Metastatic
• Castration resistant Prostate cancer
I
NCT02740985 To determine the maximum tolerated dose of A2AR receptor antagonist AZD4635 in combination with durvalumab Durvalumab: human anti-PD-1 mAb AZD4635: A2AR receptor antagonist • Advanced solid malignancies
• NSCLC
• Metastatic castrate-resistant prostate carcinoma
• Colorectal carcinoma
I
NCT03549000 To assess the safety, tolerability, and anti-tumor activity of anti-CD73 NZV930 alone and when combined with anti-PD1 and/or A2AR inhibitor NIR178 NZV930: anti-CD73 NIR178: A2AR inhibitor PDR001: experimental anti-PD-1 • NSCLC
• Triple negative breast cancer
• Pancreatic ductal adenocarcinoma
• Colorectal cancer microsatellite stable
• Ovarian cancer
• Renal cell carcinoma
I
NCT02403193 To determine the safety, tolerability, feasibility and efficacy of A2AR inhibitor PBF-509 alone and in combination with anti-PD1 PBF-509: A2AR inhibitor PDR001: experimental anti-PD-1 NSCLC I/II
NCT03381274 To evaluate the safety, tolerability and antitumor activity of novel combination therapies (oleclumab, A2AR inhibitor AZD4635 and osimertinib) Oleclumab: human anti-CD73 mAb AZD4635: A2AR inhibitor Osimertinib: tyrosine kinase inhibitor NSCLC I/II
NCT03207867 To evaluate the efficacy and safety of A2AR antagonist (NIR178) in combination with anti-PD1 NIR178: A2AR inhibitor PDR001: experimental anti-PD-1 • NSCLC
• Renal cell cancer
• Pancreatic cancer
• Urothelial cancer
• Head and neck cancer
• Diffused large B cell
• Lymphoma
• Microsatellite stable colon cancer
• Triple negative breast cancer
• Melanoma
II